Nov/Dec2019

Latest stories

INDUSTRY TRENDS: BY THE NUMBERS

TOP 100 HEALTHCARE COMPANIES

Talent Trends: Keeping Yourself Safe When Navigating the Salary Ban

Trending Now

151 Views0 Comments
in Headlines

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

South San Francisco, CA, August 02, 2021 (Business Wire) — InterVenn Biosciences today announced the completion of a $201 million Series C financing. More

by hsandm August 4, 2021, 4:28 pm

Read More
200 Views0 Comments
in Headlines

Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal

Paris, France, August 3 2021 (CNBC) — Sanofi has agreed to buy U.S. biotech company Translate Bio in a $3.2 billion deal, as it bets on next-generation mRNA technology after setbacks in the COVID-19 vaccine race, confirming a Reuters exclusive report. More

by hsandm August 4, 2021, 4:17 pm

Read More
414 Views0 Comments
in Headlines

ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO

Milan August 2, 2021 (PRNewswire) — ElectroPhysiology Frontiers S.p.A. (EPF), announced that its Board of Directors unanimously appointed Avi Fischer, M.D. as Chief Executive Officer (CEO) of the company and a member of its Board of Directors. More

by hsandm August 2, 2021, 4:18 pm

Read More
367 Views0 Comments
in Headlines

Ultrasound Disruptor Exo Secures $220M in Series C Funding Round

Redwood City, CA, August 2 2021 (Business Wire) — Exo (pronounced “echo”), a pioneering health information and devices company, closed a $220 million Series C investment round led by RA Capital Management and joined by BlackRock, Sands Capital, Avidity Partners and Pura Vida Investments that will fund the commercialization of its handheld ultrasound device and its intuitive point-of-care ultrasound workflow solution, Exo Works. Prior investors also participated. More

by hsandm August 2, 2021, 3:59 pm

Read More
1k Views0 Comments
in Headlines

ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints

NEW YORK, July 26, 2021 (PRNewswire) — ByHeart, the baby nutrition company founded by Ron Belldegrun and Mia Funt, today announces it has secured $90M in series B funding, following their $70M series A in April 2020. This coincides with the completion of the brand’s 311 baby, multicenter clinical trial – the largest conducted by a new US infant formula brand in over 25 years – successfully meeting all of its endpoints. More

by hsandm July 26, 2021, 3:57 pm

Read More
556 Views0 Comments
in Headlines

BlueRock Therapeutics Announces New Board Chair, New President and CEO

biopharmaceutical company and wholly-owned subsidiary of Bayer AG, announced today that Emile Nuwaysir, Ph.D., current President and CEO, will transition to the position of BlueRock Board Chair, effective August 1, 2021. Current Chief Scientific Officer Seth Ettenberg, Ph.D., will assume the role of President and CEO. BlueRock will continue in its mission to create authentic cellular medicines to reverse devastating diseases and improve the human condition. More

by hsandm July 26, 2021, 3:11 pm

Read More

Nov/Dec2019

Latest stories

INDUSTRY TRENDS: BY THE NUMBERS

TOP 100 HEALTHCARE COMPANIES

Talent Trends: Keeping Yourself Safe When Navigating the Salary Ban

More stories

MOTIVIDEOS

The Cleveland Clinic Top 10 Innovations

KPMG REPORT ON MEDICAL DEVICES 2030

THE REGULATORY ATMOSPHERE: Execs From Smiths, Transenterix, Bausch and Tandem Offer Insights

Olympus Executive Director of Marketing, Peter Crowley, on Improving Patient Outcomes by Keeping the Focus on People

Senior Sales Director at Lilly and Company on the Lessons He Learned in War

November / December 2019

InterVenn Biosciences Raises $201 Million for AI-driven Glycoproteomic Platform, Liquid-Biopsy development

Sanofi agrees to buy U.S. mRNA partner Translate Bio in $3.2 billion deal

ElectroPhysiology Frontiers announces appointment of Avi Fischer, M.D. as CEO

Ultrasound Disruptor Exo Secures $220M in Series C Funding Round

ByHeart Secures $90M Series B Financing and Achieves All of its Clinical Trial Endpoints

BlueRock Therapeutics Announces New Board Chair, New President and CEO

Latest stories

More stories

Log In

Sign In

Forgot password?

Your password reset link appears to be invalid or expired.

Log in

Privacy Policy

Add to Collection

No Collections